*Enough cash till 2Q19 *Confident and strong management team. *$2 B Annual U.S vaccine market. *Especially 2018 is the year people suffer from flu . FDA may give green light to ALT for their studies . NasoVax . *Stock is under accumulations since 6 months . *Ceo Bill Enright has been with the company over 10yrs , its time for him to prove himself. *Heavy insider buying activities.